Consistency of quality attributes for the glycosylated monoclonal antibody Humira® (adalimumab)

References

• Abbvie Inc. Humira® [package insert]. North Chicago, IL: 2014.
   Google Scholar
• Burmester GR, Panaccione R, Gordon KB, McIlraith MJ, Lacerda AP. Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease. Ann Rheum Dis 2013; 72:517-24; PMID:22562972; http://dx.doi.org/10.1136/annrheumdis-2011-201244
   PubMed Web of Science ®Google Scholar
• Gordon K, Papp K, Poulin Y, Gu Y, Rozzo S, Sasso EH. Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL. J Am Acad Dermatol 2012; 66:241-51; PMID:21752491; http://dx.doi.org/10.1016/j.jaad.2010.12.005
   PubMed Web of Science ®Google Scholar
• Keystone EC, van der Heijde D, Kavanaugh A, Kupper H, Liu S, Guerette B, Mozaffarian N. Clinical, functional, and radiographic benefits of longterm adalimumab plus methotrexate: final 10-year data in longstanding rheumatoid arthritis. J Rheumatol 2013; 40:1487-97; PMID:23818718; http://dx.doi.org/10.3899/jrheum.120964
   PubMed Web of Science ®Google Scholar
• Schiestl M, Stangler T, Torella C, Cepeljnik T, Toll H, Grau R. Acceptable changes in quality attributes of glycosylated biopharmaceuticals. Nat Biotechnol 2011; 29:310-2; PMID:21478841; http://dx.doi.org/10.1038/nbt.1839
   PubMed Web of Science ®Google Scholar
• Schneider CK. Biosimilars in rheumatology: the wind of change. Ann Rheum Dis 2013; 72:315-8; PMID:23390018; http://dx.doi.org/10.1136/annrheumdis-2012-202941
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. 2014. Humira procedural steps taken and scientific information after authorization. Available from: http://www.ema.europa.eu (accessed 15 September 2014)
   Google Scholar
• International Conference on Harmonisation Guidance on Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biologics Products; 1999 ( Federal Register 64:44928)
   Google Scholar
• Kozlowski S, Woodcock J, Midthun K, Sherman RB. Developing the nation's biosimilars program. N Engl J Med 2011; 365:385-8; PMID:21812668; http://dx.doi.org/10.1056/NEJMp1107285
   PubMed Web of Science ®Google Scholar
• Abes R, Teillaud J. Impact of glycosylation on effector functions of therapeutic IgG. Pharmaceuticals 2010; 3:146-57; http://dx.doi.org/10.3390/ph3010146
   Google Scholar
• Antes B, Amon S, Rizzi A, Wiederkum S, Kainer M, Szolar O, Fido M, Kircheis R, Nechansky A. Analysis of lysine clipping of a humanized Lewis-Y specific IgG antibody and its relation to Fc-mediated effector function. J Chromatogr B Analyt Technol Biomed Life Sci. 2007; 852:250-6; PMID:17296336; http://dx.doi.org/10.1016/j.jchromb.2007.01.024
   PubMed Web of Science ®Google Scholar
• Anthony RM, Ravetch JV. A novel role for the IgG Fc glycan: the anti-inflammatory activity of sialylated IgG Fcs. J Clin Immunol 2010; 30 Suppl 1:S9-14; PMID:20480216; http://dx.doi.org/10.1007/s10875-010-9405-6
   PubMedGoogle Scholar
• Bohm S, Schwab I, Lux A, Nimmerjahn F. The role of sialic acid as a modulator of the anti-inflammatory activity of IgG. Sem Immunopathol 2012; 34:443-53; http://dx.doi.org/10.1007/s00281-012-0308-x
   PubMed Web of Science ®Google Scholar
• Chirino AJ, Mire-Sluis A. Characterizing biological products and assessing comparability following manufacturing changes. Nat Biotechnol 2004; 22:1383-91; PMID:15529163; http://dx.doi.org/10.1038/nbt1030
   PubMed Web of Science ®Google Scholar
• Lux A, Nimmerjahn F. Impact of differential glycosylation on IgG activity. Adv Exp Med Biol 2011; 780:113-24; PMID:21842369; http://dx.doi.org/10.1007/978-1-4419-5632-3_10
   PubMed Web of Science ®Google Scholar
• Dick LW, Jr., Kim C, Qiu D, Cheng KC. Determination of the origin of the N-terminal pyro-glutamate variation in monoclonal antibodies using model peptides. Biotechnol Bioeng 2007; 97:544-53; PMID:17099914; http://dx.doi.org/10.1002/bit.21260
   PubMed Web of Science ®Google Scholar
• Khawli LA, Goswami S, Hutchinson R, Kwong ZW, Yang J, Wang X, Yao Z, Sreedhara A, Cano T, Tesar D, et al. Charge variants in IgG1: Isolation, characterization, in vitro binding properties and pharmacokinetics in rats. mAbs 2010; 2:613-24; PMID:20818176; http://dx.doi.org/10.4161/mabs.2.6.13333
   PubMed Web of Science ®Google Scholar
• Jiang XR, Song A, Bergelson S, Arroll T, Parekh B, May K, Chung S, Strouse R, Mire-Sluis A, Schenerman M. Advances in the assessment and control of the effector functions of therapeutic antibodies. Nat Rev Drug Discov 2011; 10:101-11; PMID:21283105; http://dx.doi.org/10.1038/nrd3365
   PubMed Web of Science ®Google Scholar
• Jefferis R. Antibody therapeutics: isotype and glycoform selection. Expert Opin Biol Ther 2007; 7:1401-13; PMID:17727329; http://dx.doi.org/10.1517/14712598.7.9.1401
   PubMed Web of Science ®Google Scholar
• Lee S, Raw A, Yu L, Lionberger R, Ya N, Verthelyi D, Rosenberg A, Kozlowski S, Webber K, Woodcock J. Scientific considerations in the review and approval of generic enoxaparin in the United States. Nat Biotechnol 2013; 31:220-6; PMID:23471071; http://dx.doi.org/10.1038/nbt.2528
   PubMed Web of Science ®Google Scholar
• Raju TS, Jordan RE. Galactosylation variations in marketed therapeutic antibodies. mAbs 2012; 4:385-91; PMID:22531450; http://dx.doi.org/10.4161/mabs.19868
   PubMed Web of Science ®Google Scholar
• Alessandri L, Ouellette D, Acquah A, Rieser M, Leblond D, Saltarelli M, Radziejewski C, Fujimori T, Correia I. Increased serum clearance of oligomannose species present on a human IgG1 molecule. mAbs 2012; 4:509-20; PMID:22669558; http://dx.doi.org/10.4161/mabs.20450
   PubMed Web of Science ®Google Scholar
• Dalziel M, Crispin M, Scanlan CN, Zitzmann N, Dwek RA. Emerging principles for the therapeutic exploitation of glycosylation. Science 2014; 343:1235681; PMID:24385630; http://dx.doi.org/10.1126/science.1235681
   PubMed Web of Science ®Google Scholar
• Ebbers HC, van Meer PJ, Moors EH, Mantel-Teeuwisse AK, Leufkens HG, Schellekens H. Measures of biosimilarity in monoclonal antibodies in oncology: the case of bevacizumab. Drug Discov Today 2013; 18:872-9; PMID:23688584; http://dx.doi.org/10.1016/j.drudis.2013.05.004
   PubMed Web of Science ®Google Scholar
• Goetze AM, Liu YD, Zhang Z, Shah B, Lee E, Bondarenko PV, Flynn GC. High-mannose glycans on the Fc region of therapeutic IgG antibodies increase serum clearance in humans. Glycobiology 2011; 21:949-59; PMID:21421994; http://dx.doi.org/10.1093/glycob/cwr027
   PubMed Web of Science ®Google Scholar